Motavizumab: Difference between revisions
No edit summary |
No edit summary |
||
| Line 49: | Line 49: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Motavizumab''' (proposed [[International Nonproprietary Name|INN]], trade name '''Numax''') is a [[humanized monoclonal antibody]]. It is being investigated by [[MedImmune]] (today a subsidiary of [[AstraZeneca]]) for the prevention of [[respiratory syncytial virus]] infection in high-risk [[infant]]s. {{As of|September 2009}}, it is undergoing Phase II and III [[clinical trials]].<ref>[http://www.clinicaltrials.gov/ct2/results?term=motavizumab ClinicalTrials.gov]</ref> | '''Motavizumab''' (proposed [[International Nonproprietary Name|INN]], trade name '''Numax''') is a [[humanized monoclonal antibody]]. It is being investigated by [[MedImmune]] (today a subsidiary of [[AstraZeneca]]) for the prevention of [[respiratory syncytial virus]] infection in high-risk [[infant]]s. {{As of|September 2009}}, it is undergoing Phase II and III [[clinical trials]].<ref>[http://www.clinicaltrials.gov/ct2/results?term=motavizumab ClinicalTrials.gov]</ref> | ||
| Line 66: | Line 62: | ||
[[Category:AstraZeneca]] | [[Category:AstraZeneca]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
{{monoclonal-antibody-stub}} | {{monoclonal-antibody-stub}} | ||
Revision as of 13:29, 7 April 2015
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | RSV glycoprotein F |
| Clinical data | |
| Trade names | Numax |
| Routes of administration | i.v. |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | None |
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C6476H10014N1706O2008S48 |
| Molar mass | Approximately 148 kDa |
  (what is this?) (verify) | |
|
WikiDoc Resources for Motavizumab |
|
Articles |
|---|
|
Most recent articles on Motavizumab Most cited articles on Motavizumab |
|
Media |
|
Powerpoint slides on Motavizumab |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Motavizumab at Clinical Trials.gov Clinical Trials on Motavizumab at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Motavizumab
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Motavizumab Discussion groups on Motavizumab Patient Handouts on Motavizumab Directions to Hospitals Treating Motavizumab Risk calculators and risk factors for Motavizumab
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Motavizumab |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009[update], it is undergoing Phase II and III clinical trials.[1]
In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.[2]
In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[3]
References
- ↑ ClinicalTrials.gov
- ↑ "FDA Panel Nixes Licensing Request for Motavizumab". Medscape. 3 June 2010. Retrieved 2014-03-02.
- ↑ "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21.
 | This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
- Pages with script errors
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Infobox drug tracked parameters
- Drugs that are a monoclonal antibody
- Articles containing potentially dated statements from September 2009
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- AstraZeneca
- Drug
- Monoclonal antibody stubs